We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Health Canada Details Evidence Needed In Postmarket Benefit-Risk Assessments
Health Canada Details Evidence Needed In Postmarket Benefit-Risk Assessments
May 8, 2014
Drugmakers providing postmarket benefit-risk assessments to Health Canada will soon need to follow rigid, standardized guidelines that provide both preapproval and postapproval data about a drug’s efficacy.